Yikon Genomics

Yikon Genomics, founded in 2012 and based in Shanghai and Suzhou, is dedicated to advancing reproductive health and personalized cancer genetic services. We operate a medical laboratory in Suzhou and have offices in Hong Kong, Spain, and Malaysia, making high-quality genetic services accessible globally. Our mission, "Innovate for the Health of Billions," drives our work in single-cell whole genome amplification and sequencing technology. Leveraging AI and machine learning, we offer decentralized and cost-effective genetic testing solutions for reproductive challenges and genetic risks. We innovate continuously, with key advancements including NICS (niPGT-A) and the first NICS baby in 2016, and the development of ERT in 2018, supporting families worldwide in achieving healthy live births. Our strengths lie in our continuous innovation, rigorous clinical validation (including IVD applications and RCTs), strong execution, and ability to translate scientific research into clinical applications. These strengths result in decentralized, cost-effective, and rapid turnaround genetic services. With a presence in over 600 medical institutions, including more than 200 reproductive centers across 40+ countries, our vision is to help 100 million families improve their health and become the leading brand in precision medicine, supporting successful treatment outcomes with sustainable practices.